Lab urges FDA to suspend ranitidine sales due to degradation risk 13-Jan-2020 By Nick Taylor Emery Pharma files citizen petition arguing data on the degradation of ranitidine supports suspension of the medicine.
Mylan recalls close-to-expiration nizatidine capsules over NDMA impurity 09-Jan-2020 By Ben Hargreaves The recall of products due to NDMA contamination continues, with a new medication, nizatidine, now thought to be affected by the probable carcinogen.
NDMA investigation leads to cases discovered in diabetes treatment 09-Dec-2019 By Ben Hargreaves After NDMA contamination is found by Singaporean authorities, both the FDA and EMA state they are working on the testing of metformin treatments.
Sanofi and Dr Reddy’s join the ranitidine recall 24-Oct-2019 By Ben Hargreaves Both companies issue a voluntary recall of their ranitidine-based products due to the ongoing investigation into cancer-causing contamination.
Ranitidine recalls sweep globe 26-Sep-2019 By Ben Hargreaves US, Canadian, South Korean, and Indian authorities recommend the recall of certain ranitidine medicines due to cancer-causing impurity.
Sandoz expands recall to include all lots of ranitidine 24-Sep-2019 By Ben Hargreaves Sandoz has moved to recall all quantities and lots of ranitidine hydrochloride capsules from the US market due to contamination with NDMA.
Fears over antacid medicine spark ‘industry-wide recalls’ 19-Sep-2019 By Ben Hargreaves Sandoz announces that it will recall its ranitidine medicine, as part of what a spokesperson said were a series of recalls across the industry.
Further NDMA contamination discovery prompts lawsuit 17-Sep-2019 By Ben Hargreaves Both the FDA and EMA announce NDMA contamination of ranitidine medicines and a lawsuit is immediately filed against manufacturers for ‘concealing’ the carcinogen.